Topic Intelligence: azn

simplywall.st • 1d ago

Novartis (SWX:NOVN) Is Buying Myricx Bio For Up To $1.5 Billion

Novartis (SWX:NOVN) has agreed to acquire UK based Myricx Bio, a privately held biotechnology company. Myricx Bio focuses on first in class N myristoy...

Bullish 65.0

finance.yahoo.com • 1d ago

Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​de...

Neutral 0.0

finance.yahoo.com • 1d ago

Novartis (SWX:NOVN) To Acquire Myricx Bio In $1.5 Billion Oncology Deal

Novartis (SWX:NOVN) has agreed to acquire UK-based Myricx Bio in a transaction valued at up to US$1.5b. The deal includes US$1.1b in upfront and miles...

Bullish 78.5

finance.yahoo.com • 1d ago

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable dise...

Neutral 0.0

kalkinemedia.com • 1d ago

Why Are Traders Rechecking AstraZeneca And Genus As Healthcare Sentiment Shifts?

Why Are Traders Rechecking AstraZeneca And Genus As Healthcare Sentiment Shifts?

Neutral 0.0

finance.yahoo.com • 1d ago

Real-World Evidence for Real-Life Solutions: CCRAN and Signal49 Research Launch Phase II of Path-Defining Comprehensive Genomic Profiling Initiative

The Colorectal Cancer Resource & Action Network (CCRAN) today announced that Phase II of its genomic profiling research initiative is underway, contin...

Neutral 0.0

finance.yahoo.com • 1d ago

Real-World Evidence for Real-Life Solutions: CCRAN and Signal49 Research Launch Phase II of Path-Defining Comprehensive Genomic Profiling Initiative

The Colorectal Cancer Resource & Action Network (CCRAN) today announced that Phase II of its genomic profiling research initiative is underway, contin...

Neutral 0.0

finance.yahoo.com • 1d ago

Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry

Kailera’s in-licensed oral weight loss drug is currently in a global Phase II study for obesity.

Neutral 0.0

finance.yahoo.com • 1d ago

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight

Recently published Post-Bariatric Hypoglycemia Market Insights report includes a comprehensive understanding of current treatment practices, post-bari...

Strong Bullish 88.6

finance.yahoo.com • 1d ago

BostonGene Named "Overall AI-based Analytics Company of the Year" in 2026 AI Breakthrough Awards Program

WALTHAM, Mass., July 07, 2026--BostonGene, leading developer of AI models for tumor and immune biology, today announced that it has been selected as w...

Strong Bullish 100.0